Clinical Trial Update: Lanreotide as Treatment of Polycystic Livers [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 clinical trial of lanreotide for polycystic liver disease has completed, indicating ongoing evaluation for this indication.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Polycystic Kidney Disease
• Polycystic Liver Disease

Drugs mentioned

• Lanreotide (lanreotide)

Snippet

Sponsor: Radboud University Medical Center | Conditions: Polycystic Liver Disease, Hepatomegaly | Phase 2, Phase 3 | Status: COMPLETED